CXCR4 and non-Hodgkin lymphoma: In a cohort of 20 non-Hodgkin lymphoma patients, a significantly better prognosis and favorable treatment response was observed for patients experiencing a post-treatment decrease in CXCR4 expression in the bone marrow [31].